Novel Gallium 68 Citrate in Orthopedic Infections

Joint Prosthesis Clinical Trial

Official title:
Novel Gallium 68 Citrate in Orthopedic Infections

Status Terminated

Clinical Trial Summary

In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan. We will perform PET/CT scan with 68Gallium citrate and 18F-FDG in subjects with failed hip or knee prosthesis. Both 68Gallium-citrate and 18F-FDG scans, done within 24-48 hours from each other, will be performed within 4 weeks before surgical evaluation/revision of the hardware.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03123289
Study type	Interventional
Source	Rutgers, The State University of New Jersey
Contact
Status	Terminated
Phase	Phase 2
Start date	March 6, 2017
Completion date	October 14, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02177097` - Chronic Pain, Inflammation and Infection After Joint Replacement	N/A
	Completed	`NCT00211926` - StaphVAX Immunogenicity in Orthopedic Implant Patients	Phase 3